What Is EURneffy?
EURneffy is the first nasal spray in the UK to deliver adrenaline for the rapid treatment of anaphylaxis — a severe allergic reaction that can happen quickly after contact with allergens like certain foods, insect stings, or medications. Symptoms can include breathing difficulties, throat and airway swelling, and dangerously low blood pressure, all requiring urgent adrenaline treatment.
Traditionally, adrenaline has been administered using needle-based devices known as adrenaline auto-injectors (AAIs), which deliver the medication into the thigh muscle. EURneffy changes that by providing a needle-free option: a 2 mg dose of adrenaline delivered via the nasal route.
Approved for individuals weighing at least 30kg (around 66 pounds), this new method may offer a more accessible and less intimidating alternative, especially for those with needle anxiety.
How does EURneffy work?
Each EURneffy device is preloaded with a single 2 mg dose of adrenaline and is ready to use. To administer:
- Insert the nozzle into one nostril.
- Press the plunger to release the medication.
The adrenaline is absorbed through the nasal lining and rapidly enters the bloodstream—even if the nose is congested due to allergies or illness. Once in the body, adrenaline acts quickly to:
- Constrict blood vessels to counteract low blood pressure,
- Relax the muscles in the airways to improve breathing,
- Reduce swelling and skin reactions like hives.
As with AAIs, people prescribed EURneffy will be advised to carry two devices, in case a second dose is required. Training and detailed instructions will be included with the prescription.
Why this matters:
Quick administration of adrenaline during anaphylaxis is critical to avoid serious outcomes. Yet, some individuals delay using AAIs due to needle phobia or uncertainty about how to use them.
EURneffy’s needle-free format could lower these barriers, enabling faster and more confident action during emergencies. Its compact and portable design also makes it easy to carry, encouraging users to keep it close at all times.
By offering an alternative delivery method, EURneffy has the potential to improve access to timely treatment when every second counts.
What it means for Allergy Management:
Although EURneffy is expected to launch in the UK toward the end of 2025, availability will depend on factors like final regulatory steps, pricing agreements, and healthcare provider readiness. Current users of AAIs won’t be automatically switched — any transition to EURneffy will be guided by discussions between patients and their healthcare providers to determine the most suitable option.
A lower-dose version (1 mg), intended for children weighing between 15–30 kg (33–66 pounds), has already received approval in the United States and is currently under review in Europe. A UK release of this child-specific version is anticipated in 2026.
In summary, EURneffy represents a significant advancement in anaphylaxis care, offering a new, user-friendly method for delivering life-saving adrenaline.
Staying prepared:
Those at risk of anaphylaxis are advised to:
- Always carry two of your prescribed adrenaline devices.
- Ensure friends, family or caregivers know how to assist in an emergency.
- Familiarise yourself with the instructions for your device.
- Report any concerns or side effects to your GP, pharmacist or the MHRA Yellow Card scheme:Yellow Card | Making medicines and medical devices safer
- For guidance on recognising and responding to anaphylaxis, visit the page: About Anaphylaxis | Anaphylaxis UK
- The MHRA press release can be read here: MHRA approves adrenaline nasal spray - the first needle-free emergency treatment for anaphylaxis in the UK - GOV.UK